A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to ...
Results that may be inaccessible to you are currently showing.